Psoriasisisachronicinflammatoryskindiseasecharacterizedbyepidermalhyperplasia(Acanthosis)withelongatedridgesandabnormaldifferentiationofepidermalkeratinocytes,dermalangiogenesis,abnormalaccumulationofpolymorphonuclearleukocytes,infiltrationofactivatedTcellsanddendriticcells,andincreasedcytokinelevels.MatTekhasdevelopedinvitromodelofPsoriasistoenablethestudyofthedisease,andtoscreentherapeuticcandidatesforsafetyandefficacy.

MatTek’sdiseased3Dmodelofpsoriasisisproducedfromnormalhumanepidermalkeratinocytesandpsoriaticfibroblastsharvestedfrompsoriaticlesions.Thecellsareculturedonspeciallypreparedcellcultureinsertsusingserumfreemediumtoformamultilayered,highlydifferentiatedtissue.ThePsoriasistissuesmaintainapsoriaticphenotypeasevidencedbyincreasedbasalcellproliferation,expressionofpsoriasis-specificMarkersandelevatedreleaseofpsoriasis-specificcytokines.Morphologically,thetissuemodelcloselyparallelslesionalpsoriatichumantissues.Thismodelprovidesresearcherswithahumanrelevant,highlycontrolledinvitromodeltoassessthesafetyandefficacyofleadtherapeuticcompoundsandtostudyotherbasicpsoriasisBIOLOGyphenomena.

Thepsoriasistissuemodelexhibitsapsoriaticphenotypeasevidencedbyincreasedexpressionofpsoriasis-associatedmarkersincludinghumanβ-defensin-2(HBD2),psoriasin,SKALP/elafin,keratinocytehyperproliferativecellsandproinflammatorycytokines/chemokinessuchasIL-6,IL-8,GM-CSF,andIP-10. Additionally,MatTek’sPsoriasismodelcanbeproducedfrom6differentdonorsallowingforthestudyoftherapeuticswhileaccountingforbiologicalvariABIlitybetweendonors.

TheinvitroPsoriasismodelisresponsivetomarketedanti-psoriatictherapeuticsandisamenabletomodelskin–immunesysteminteractionswiththeexogenousadditionofsolubleimmunecellfactors.


Themodelprovidesresearcherswithauseful,invitromeanstoassessthepre-clinicalsafetyandefficacyofleadtherapeuticcompounds.
PsoriasisApplicationNote
Thetissuemodelcloselyparallelslesionalpsoriatichumantissuesintermsofmorphologyandcytokineexpression.Thismodelprovidesresearcherswithauseful,invitromeanstostudypsoriasisbiologyphenomena.
Searchourlibraryoftechnicalpapersformoreinformation.
Kit:ThePsoriasisTissueKit(SOR-300-FT)consistsof24tissues.
Substrate:MilliporeMillicell™Cellcultureinsertused.Poresize=0.4μm,Diameter=0.8cm,Surfacearea=0.6cm2.
Culture:Atairliquidinterface(apicaltissuesurfaceexposedtotheatmosphere).
Histology:8-12celllayersplusstratumcorneum(basal,spinous,andgranularlayers).
LotNumbers:Tissuelotsareproducedeveryotherweekandareassignedaspecificlotnumber.Aletterofthealphabetisappendedtotheendofthelotnumbertodifferentiatebetweenindividualkitswithinagivenlotoftissues.Alltissuekitswithinalotareidenticalinregardstocells,medium,handling,cultureconditions,etc.
Shipment:At2-8°Conmedium-supplemented,agarosegelsin24-wellplates.
Shipmentday:EveryotherMonday.
Delivery:TuesdaymorningviaFedExpriorityservice(US).OutsideUS:Tuesday-Thursdaydependingonlocation.
Shelflife:Includingtimeintransit,tissuesmaybestoredintheiroriginalpackageat2-8°Cforupto4dayspriortouse.Thebestreproducibilitywillbeobtainediftissuesareusedconsistentlyonthesameday,e.g.Tuesdayafternoonorfollowingovernightstorageat2-8°C(Wednesdaymorning).Extendedstorageperiodsarenotrecommended.
Lengthofexperiments:Culturescanbecontinuedforupto2weekswithgoodretentionofnormalepidermalmorphology.Culturesmustbefedeveryotherdaywith5.0mlofSOR-300-FT-MMmedium.Culturestands(MatTekpart#:MEL-STND)arerequiredforexperimentsinexcessof24hrs.
SOR-300-FT-ABF:Antibiotic-freetissue.Forlast3daysofculture,gentamicinisomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.
SOR-300-FT-AFF:Anti-fungal-freetissue.Forlast3daysofculture,Amphotericinisomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.
SOR-300-FT-AFAB:Antibiotic,anti-fungal-freetissue.Forlast3daysofculture,gentamicinandAmphotericinareomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.
SOR-300-FT-CTR:Normalhealthycontroltissueforpsoriasisexperiments
Type:Normalhumanepidermalkeratinocytes(NHEK);psoriatichumandermalfibroblasts(PHDF).
Derivedfrom:Neonatal-foreskintissue(NHEK);adultpsoriaticexplants(PHDF)
Screenedfor:HIV,Hepatitis-B,Hepatitis-C,andmycoplasma.
Basemedium:Dulbecco’sModifiedEagle’sMedium(DMEM).
Growthfactors/hormones:Epidermalgrowthfactor,insulin,hydrocortisoneandotherproprietarystimulatorsofepidermaldifferentiation.
Serum:None.
Antibiotics:Gentamicin5µg/ml(10%ofthenormalgentamicinlevel).
Anti-fungalagent:AmphotericinB0.25µg/ml.
pHIndicator:Phenolred.
Otheradditives:Lipidprecursorsusedtoenhanceepidermalbarrierformation(proprietary).
Alternatives:Phenolred-free(SOR-300-FT-PRF),antibiotic-free(SOR-300-FT-ABF),anti-fungal-free(SOR-300-FT-AFF),orhydrocortisone-freemediumandtissue(SOR-300-FT-HCF)areavailable.Agentsareremoved3dayspriortoshipment.
Assay/Maintenancemedium:SOR-300-FT-MMisusedforequilibrationoftissuesfollowingshipmentandformaintenanceoftheSOR-300-FTtissuesincultureduringexperiments.
Visualinspection:Alltissuesarevisuallyinspectedandifphysicalimperfectionsarenoted,tissuesarerejectedforshipment.
End-usetesting:Tissuesareexposedto1%TritonX-100for4,6,8and10hours.Thetimeofexposurerequiredtoreducethetissueviability(ET-50)usingtheMTTviabilityassayisdetermined(SeeMatTekPsoriasisTissueuseprotocol)foreachlotoftissue.ET-50’sgenerallyfallwithintherangeof6.0-12.0hours.ET-50’sincustomers’labmaydifferslightlyfromtheMatTekresults.Inaddition,qPCRdataforpsoriasisrelatedgeneswillbemonitored.Increasesof>5foldforpsoriasin,humanbeta-defensin-2andelafinareexpected.
Sterility:Allmediausedthroughouttheproductionprocessischeckedforsterility.Maintenancemediumisincubatedwithandwithoutantibioticsfor1weekandcheckedforsterility.Theagarosegelfromthe24-wellplateusedforshippingisalsoincubatedfor1weekandcheckedforanysignofcontamination.
Screeningforpathogens:AllcellsarescreenedandarenegativeforHIV,hepatitisBandhepatitisCusingPCR.However,noknowntestmethodcanoffercompleteassurancethatthecellsarepathogenfree.Thus,theseproductsandallhumanderivedproductsshouldbehandledatBSL-2levels(biosafetylevel2)orhigherasrecommendedintheCDC-NIHmanual,“Biosafetyinmicrobiologicalandbiomedicallaboratories,”1998.Forfurtherassistance,pleasecontactyoursiteSafetyOfficerorMatTektechnicalservice.
Notificationoflotfailure:IfatissuelotfailsourQCorsterilitytesting,thecustomerwillbenotifiedandthetissueswillbereplacedwithoutchargewhenappropriate.BecauseourQCandsterilitytestingisdonepost-shipment,notificationwillbemadeassoonaspossIBLe(Undernormalcircumstances,ET-50failureswillbenotifiedbyThursday5pm;sterilityfailureswillbenotifiedwithin8daysofshipment).
matriks/Shikari® (S-ATP) Anti-Pembrolizumab ELISA w/confirmation/PEM-QNS-KEY
intactgenomics/Methionine Auxotrophic LBA4404 | ig® | Intact Genomics/15x50μl/1076-15
goprolytix/Proteolytic Activation of Prothrombin/1 mg, 200 µg/BCT-DFP
novateinbio/Dynorphin A ( 13-17 ) Porcine Peptide/5mg/PE-54024_5mg
matriks/Shikari® (Q-ETA) Etanercept ELISA/ETA-FD-ENB
intactgenomics/Agrobacterium ElectroComponent Combo Pack | Intact Genomics/12x50µl/1290-24
Jackson/Peroxidase AffiniPure Goat Anti-Mouse IgG (H+L)/2.0 ml/115-035-003
Jackson/Peroxidase AffiniPure Goat Anti-Rabbit IgG (H+L)/2.0 ml/111-035-003
Qubit™ dsDNA BR Assay Kit Q32853现货
Invitrogen Q32855 Qubit™ RNA HS Assay Kit现货促销
LUCK-1G,D-Luciferin, Potassium Salt 钾盐现货
GoldBio/D-Luciferin, Sodium Salt (Proven and Published)/LUCNA-1G/1 g